Is Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Trading At A 35% Discount?
Jan 19
Have your own idea? Try our Stock Screener
Chinese (SSE) Healthcare Sector Analysis
UpdatedJan 21, 2025
DataAggregated Company Financials
Companies469
- 7D3.2%
- 3M-7.6%
- 1Y-4.2%
- YTD-0.9%
The Healthcare industry is up 2.6% in the last week, with Jiangsu Hengrui Medicine up 4.0%. However, the industry is down 9.3% over the past year. Looking forward, earnings are forecast to grow by 28% annually.
Sector Valuation and Performance
Has the Chinese Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 21 Jan 2025 | CN¥5.4t | CN¥2.2t | CN¥153.7b | 30.8x | 35.1x | 2.4x |
| Thu, 19 Dec 2024 | CN¥5.8t | CN¥2.2t | CN¥153.7b | 33.3x | 37.7x | 2.6x |
| Sat, 16 Nov 2024 | CN¥5.9t | CN¥2.2t | CN¥154.1b | 33.7x | 38.1x | 2.6x |
| Mon, 14 Oct 2024 | CN¥5.7t | CN¥2.2t | CN¥161.8b | 32.1x | 35.2x | 2.5x |
| Wed, 11 Sep 2024 | CN¥4.8t | CN¥2.2t | CN¥162.1b | 27.4x | 29.8x | 2.2x |
| Fri, 09 Aug 2024 | CN¥5.2t | CN¥2.3t | CN¥166.2b | 28.4x | 31.4x | 2.3x |
| Sun, 07 Jul 2024 | CN¥5.1t | CN¥2.3t | CN¥165.0b | 27.8x | 31.2x | 2.3x |
| Tue, 04 Jun 2024 | CN¥5.6t | CN¥2.3t | CN¥164.9b | 29.9x | 33.8x | 2.5x |
| Thu, 02 May 2024 | CN¥5.9t | CN¥2.3t | CN¥169.1b | 32.3x | 35x | 2.6x |
| Sat, 30 Mar 2024 | CN¥5.8t | CN¥2.3t | CN¥174.2b | 30.4x | 33.1x | 2.5x |
| Mon, 26 Feb 2024 | CN¥5.8t | CN¥2.3t | CN¥179.6b | 28.8x | 32.3x | 2.5x |
| Wed, 24 Jan 2024 | CN¥5.8t | CN¥2.3t | CN¥176.9b | 29.3x | 32.5x | 2.5x |
| Fri, 22 Dec 2023 | CN¥6.4t | CN¥2.3t | CN¥177.1b | 34.4x | 36.2x | 2.8x |
| Sun, 19 Nov 2023 | CN¥6.6t | CN¥2.3t | CN¥177.2b | 36x | 37.4x | 2.9x |
| Tue, 17 Oct 2023 | CN¥6.6t | CN¥2.3t | CN¥185.1b | 34.1x | 35.5x | 2.9x |
| Thu, 14 Sep 2023 | CN¥6.2t | CN¥2.3t | CN¥186.4b | 31.6x | 33.1x | 2.7x |
| Sat, 12 Aug 2023 | CN¥6.4t | CN¥2.3t | CN¥193.5b | 32.2x | 32.9x | 2.8x |
| Mon, 10 Jul 2023 | CN¥6.5t | CN¥2.3t | CN¥191.9b | 33.4x | 33.8x | 2.9x |
| Wed, 07 Jun 2023 | CN¥6.8t | CN¥2.3t | CN¥191.5b | 35.2x | 35.3x | 3x |
| Fri, 05 May 2023 | CN¥7.1t | CN¥2.3t | CN¥194.6b | 37.1x | 36.7x | 3.2x |
| Sun, 02 Apr 2023 | CN¥7.1t | CN¥2.2t | CN¥234.4b | 37x | 30.1x | 3.1x |
| Tue, 28 Feb 2023 | CN¥7.2t | CN¥2.2t | CN¥233.0b | 38.7x | 30.9x | 3.3x |
| Thu, 26 Jan 2023 | CN¥7.4t | CN¥2.2t | CN¥233.0b | 37.8x | 31.9x | 3.4x |
| Sat, 24 Dec 2022 | CN¥6.7t | CN¥2.2t | CN¥232.0b | 35.4x | 29.1x | 3.1x |
| Mon, 21 Nov 2022 | CN¥7.3t | CN¥2.2t | CN¥231.8b | 40x | 31.3x | 3.3x |
| Wed, 19 Oct 2022 | CN¥6.8t | CN¥2.1t | CN¥228.3b | 36.4x | 30x | 3.2x |
| Fri, 16 Sep 2022 | CN¥6.4t | CN¥2.1t | CN¥223.4b | 32.4x | 28.5x | 3x |
| Sun, 14 Aug 2022 | CN¥6.7t | CN¥2.1t | CN¥228.1b | 33.3x | 29.2x | 3.2x |
| Tue, 12 Jul 2022 | CN¥7.0t | CN¥2.1t | CN¥224.6b | 34.5x | 31.2x | 3.4x |
| Thu, 09 Jun 2022 | CN¥6.5t | CN¥2.0t | CN¥226.1b | 33.6x | 28.5x | 3.1x |
| Sat, 07 May 2022 | CN¥6.2t | CN¥2.0t | CN¥227.4b | 30.3x | 27.3x | 3x |
| Mon, 04 Apr 2022 | CN¥7.0t | CN¥2.0t | CN¥213.4b | 35.7x | 32.7x | 3.6x |
| Wed, 02 Mar 2022 | CN¥7.1t | CN¥1.9t | CN¥212.0b | 35.6x | 33.4x | 3.6x |
| Fri, 28 Jan 2022 | CN¥6.7t | CN¥1.9t | CN¥205.0b | 35.2x | 32.9x | 3.5x |
Price to Earnings Ratio
32.9x
Current Industry PE
- Investors are relatively neutral on the Chinese Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 32.5x.
- The 3-year average PS ratio of 2.9x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have declined 9.2% per year over the last three years.
- Meanwhile revenues for these companies have grown 5.1% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare sector?
| CN Market | 4.24% | |
| Healthcare | 3.20% | |
| Life Sciences | 4.06% | |
| Healthtech | 3.78% | |
| Pharma | 3.53% | |
| Biotech | 3.16% | |
| Medical Equipment | 2.83% | |
| Healthcare Services | 2.01% | |
Industry PE
- Investors are most optimistic about the Healthtech industry, which is trading close to its 3-year average PE ratio of 363x.
- Analysts are expecting annual earnings growth of 48.6%, which is higher than its past year's earnings decline of 19.7% per year.
- Investors are most pessimistic about the Healthcare Services industry, which is trading below its 3-year average of 29.4x.
Forecasted Growth
- Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 58% over the next 5 years.
- This is better than its past earnings growth rate of 1.3% per year.
- In contrast, the Pharma industry is expected to see its earnings grow by 18% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 600276 Jiangsu Hengrui Medicine | CN¥45.13 | 1.9% +CN¥5.3b | 12.0% | PE52.7x | |
| 688278 Xiamen Amoytop Biotech | CN¥79.77 | 11.3% +CN¥3.3b | 46.3% | PE43.8x | |
| 600161 Beijing Tiantan Biological Products | CN¥20.75 | 6.8% +CN¥2.6b | -8.5% | PE32.2x | |
| 000963 Huadong Medicine | CN¥34.65 | 4.4% +CN¥2.6b | 5.2% | PE18.9x | |
| 300765 CSPC Innovation Pharmaceutical | CN¥28.20 | 4.9% +CN¥1.9b | -2.8% | PE76.5x |
